HW-021199

N/A

Report date: 2025/03/06 17:58:01
NME

Base Information

Drug NameHW-021199
Drug Alias NameHW-021199
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEctonucleotide pyrophosphatase/phosphodiesterase 2 inhibitors
TargetsEctonucleotide pyrophosphatase/phosphodiesterase 2
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHubei Bio-Pharmaceutical Industrial Technological Institute IncHumanwell Puracap (Likang) Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHubei Bio-Pharmaceutical Industrial Technological Institute IncHumanwell Puracap (Likang) Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A